OCD and BFRBs can look alike, but they’re not the same. Discover the similarities, important distinctions, and what they mean for treatment and recovery.

If it can bounce back and generate solid returns in the next five years, now is about as good a time as any to invest in the ...

Samsung Medical Center announced that its researchers have developed a new AI model capable of predicting the recurrence risk of non-small cell lung cancer up to a year in advance. According to the ...

Welcome to this afternoon session with Recursion. My name is Andrew Pucher. I'm part of the Healthcare Investment Banking team, and I'm joined by Ben Taylor, CFO of Recursion; and Sara Sherman, Head ...

Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, ...

Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, ...

Adding digital twin-guided ablation to a standard ablation technique improved outcomes in patients with persistent atrial fibrillation (AF), according to late-breaking research presented in a Hot Line ...

MADRID -- Extended low-dose apixaban (Eliquis) after venous thromboembolism (VTE) provoked by events like trauma or surgery in patients with obesity or other enduring risk factors dramatically reduced ...

Historic recurrence is the idea that patterns repeat over time, even if the details differ. In digital marketing, change is the only constant. Over the last 30 years, we’ve seen nonstop shifts and ...

Breast cancer types, staging, diagnosis, treatment, and survivorship are complex, but understanding them helps patients make informed care decisions. Breast cancer is a complex disease, but ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. RXRX stock looks like a deep-value growth bet at just $5 ...